At the end of March, the time had come: after only five months of construction and technology transfer, the BioNTech plant in Marburg received approval from the European Medicines Agency (EMA). Since then, batches of COVID-19 vaccine have been produced there. By the end of June, 250 million vaccine doses are planned and another 500 million by the end of the year. When fully operational, the company says it will be able to produce up to one billion doses of the vaccine annually. This would make the plant one of the largest mRNA vaccine production facilities in the world.

BioNTech thanks all of its partners, public agencies and regional authorities, service providers and suppliers who contributed to the successful opening of the plant.